Trial 4P-17-6

A phase IB open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprivation therapy and other agents in subjects with castrateresistant prostate cancer (CRPC)

Type: Treatment
Phase: Phase I
Status: Closed to Accrual with Ongoing Follow-up
Treatments: Other
Randomized: No
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Mitchell Gross, M.D.
Other Trial Staff: Cheryl Kefauver, Coordinator, Lagrimas Ilagan, D.M., Roberto Tejada, D.M., Honorina Enright, D.M., Brandi Scott, Coordinator, Charis Barg, Coordinator, Bartolo Santos, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.